States with medical marijuana laws saw 20 percent drop in some opioid prescriptions
States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center.
Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce opioid use.
Stories you may be interested in
New Feature: Calendar Integration
At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More 
Medical marijuana advocates concerned over recreational cannabis proposals
ALBUQUERQUE, N.M.— Some medical marijuana patients are concerned the proposed framework for legalizing recreational marijuana could have a potentially negative impact on the medical cannabis program. “It’s something that will devastate the medical program in doing so,” said Jason Barker, a medical cannabis advocate with Safe Access New Mexico. A special task force delivered a…
Read More 
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
Report of the Guideline Development Subcommittee of the American Academy of Neurology: We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More 
Minnesota study finds that medical pot soothes cancer pains
Symptoms such as pain and nausea improved in cancer patients who took cannabis, according to new research that is part of Minnesota’s effort to address the information void about whether marijuana offers medical benefits. Analyzing 1,120 cancer patients who received cannabis through the state medical marijuana program, researchers reported Monday that they found noteworthy improvements…
Read More 
Assessing Health-Related Outcomes of Medical Cannabis Use among Older Persons: Findings from Colorado and Illinois
ABSTRACT Objectives To assess health-related outcomes associated with medical cannabis use among older patients in Colorado and Illinois enrolled in their home state’s medical cannabis program. Methods Cross-sectional data from anonymous surveys were collected from 139 persons over the age of 60 using medical cannabis in the past year. We used structural equation modeling (SEM)…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More